A New Pharmacotherapy for Alcohol Dependence: Olanzapine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746785
Recruitment Status : Completed
First Posted : September 4, 2008
Results First Posted : March 20, 2014
Last Update Posted : March 20, 2014
Information provided by (Responsible Party):
Kent Hutchison, Ph.D., The Mind Research Network

Brief Summary:
Craving for alcohol has been related to loss of control drinking and is a major target of biological and behavioral interventions for alcohol dependence. Our previous research has demonstrated that olanzapine (a dopamine antagonist) attenuates craving for alcohol, that a variant in the gene that expresses D4 receptors influences craving for alcohol, and that olanzapine is particularly effective at reducing craving among individuals with this variant. Pilot data from a recent 12 week trial of olanzapine indicates that olanzapine is well tolerated and that olanzapine reduces drinking, particularly among individuals with the aforementioned genetic variant. The objective of the present application is to examine the effectiveness of olanzapine (5 mg/day), as compared to olanzapine (2.5 mg/day) and a placebo control, in terms of reducing craving and alcohol use behavior among treatment seeking alcoholics. Furthermore, the present application will examine whether the effects of olanzapine on drinking outcomes are mediated by its effects on a specific putative mechanism (i.e., cue-elicited craving for alcohol) and determine whether the DRD4 VNTR polymorphism is a marker for the effectiveness of olanzapine. To that end, 202 alcohol dependent subjects will be randomly assigned to medication group and receive 12 weeks of medication. Subjects will complete follow-up assessments at 3 and 6 months after the end of the treatment. It is expected that olanzapine will significantly reduce cue-elicited craving and alcohol use behavior in a dose dependent fashion over the course of the 12 week trial and follow-up period, as compared to the placebo condition. Furthermore, it is expected that the effects of olanzapine on alcohol use behavior will be mediated by the effect of olanzapine on cue-elicited craving and that the effects of olanzapine on cue-elicited craving and alcohol use behavior will be moderated by the DRD4 VNTR, such that olanzapine will be more effective among individuals with the 7 repeat allele. The successful completion of the proposed research is expected to advance a new medication for alcohol dependence and advance genetic markers that predict the effectiveness of this medication.

Condition or disease Intervention/treatment Phase
Alcohol Dependence Drug: 2.5 mg Olanzapine Drug: 5mg Olanzapine Drug: placebo Phase 3

  Hide Detailed Description

Detailed Description:

The first goal of the study is to determine whether olanzapine is effective at reducing cue-elicited craving (i.e., subjective craving as well as activation of the midbrain and prefrontal cortex after exposure to alcohol cues) for alcohol and reducing alcohol use in a sample of alcohol dependent subjects. The second goal is to test the putative mechanism of change by determining whether the effect of olanzapine on alcohol use behavior is mediated by the effect of olanzapine on cue-elicited craving. The final goal will be to examine whether genetic differences moderate the effects of olanzapine. [The polymorphism examined here involves the D4 dopamine receptor gene (DRD4), which has a variable number of tandem repeats (VNTR) in exon 3 (Van Tol et al., 1992). With respect to the DRD4 VNTR, individuals with at least one copy of an allele with 7 or more repeats are hereafter referred to as DRD4 L individuals, and individuals with alleles that have fewer than 7 repeats are hereafter referred to as DRD4 S individuals.]

In addition to laboratory studies on dopamine antagonists and alcohol craving (e.g., Modell et al., 1993; Hutchison et al., 2001), recent clinical reports have suggested that clozapine, a potent D4 receptor antagonist, reduces substance abuse among individuals with comorbid substance abuse/dependence (Green et al., 1999; Zimmet et al., 2000; Lee et al, 1998) and specifically, alcohol use (Drake et al., 2000). Animal studies have also suggested that clozapine reduces the voluntary intake of nicotine (Kameda et al., 2000). Given some of these early findings, we conducted a laboratory test of the effects of olanzapine on cue-elicited craving and craving after alcohol consumption among heavy social drinkers (Hutchison et al., 2001). We decided to test olanzapine because it also targets the D4 receptor, although not as strongly as clozapine, and because olanzapine had the best side effect profile among FDA approved medications that target dopamine receptors more broadly, and the D4 more specifically. This initial test demonstrated that olanzapine attenuated the effects of alcohol cues on two separate measures of urge to drink across two separate experimental sessions and that olanzapine prevented increases in urge to drink after alcohol consumption. With respect to the effects on urge to drink, the findings of this study are generally consistent with the theoretical premise that this appetitive behavior is partially mediated by mesolimbic dopamine activation.

To replicate and extend our previous results with olanzapine, a second study was designed to examine whether olanzapine (5 mg) reduced craving as compared to cyproheptadine (4 mg), which was used as an active control medication. It is important to note that there are no other published studies (to our knowledge) that have used such a stringent experimental control in a test of a pharmacological agent that targets alcohol craving in humans. For example, previous studies with naltrexone have utilized a placebo control only. The results from this investigation indicated that olanzapine and cyproheptadine produced equivalent levels of sedation. However, olanzapine significantly reduced craving before and after consuming alcohol, as compared to cyproheptadine (Hutchison et al., 2003). Moreover, there was a significant medication by DRD4 VNTR polymorphism interaction such that olanzapine reduced alcohol-elicited craving, particularly among DRD4 L individuals. To extend these findings, we conducted a 12 week, randomized, double-blind trial of olanzapine in the treatment of alcohol dependence (Hutchison et al., in press). Consistent with our previous studies, the results suggested that olanzapine reduced cue elicited craving and alcohol consumption significantly among DRD4 L individuals, but not DRD4 S individuals. Both of these last two studies were conducted at the Boulder GCRC.

Here, a double-blind, placebo-controlled 3 (Medication: olanzapine 5 mg, olanzapine 2.5 mg, vs. placebo) x 7 (Time: Baseline, 2, 4, 8, 12, 24, 36 weeks) mixed factorial design, where medication is a between-subjects factor and time is a within-subjects factor, will be used to test the treatment outcome hypotheses. Subjects will be randomly assigned to receive either olanzapine (5 mg), olanzapine (2.5 mg), or placebo for a period of 12 weeks such that there are equal numbers of DRD4 L individuals in each medication group. All subjects will also receive 7 sessions of medication management / supportive therapy (detailed below). Follow-up assessments will be obtained at 4, 8, 12 weeks (the end of treatment), 24 weeks, and 36 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 304 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A New Pharmacotherapy for Alcohol Dependence: Olanzapine
Study Start Date : September 2002
Actual Primary Completion Date : May 2010
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 2.5 mg Olanzapine

2.5 mg Olanzapine

1x per day for 12 weeks.

Drug: 2.5 mg Olanzapine
2.5 mg

Active Comparator: 5mg Olanzapine

5 mg Olanzapine

1x per day for 12 weeks.

Drug: 5mg Olanzapine
5 mg

Placebo Comparator: Placebo


1x per day for 12 weeks.

Drug: placebo

Primary Outcome Measures :
  1. Drinks Per Drinking Day [ Time Frame: up to 36 weeks ]
    Drinks are measured as the number of standard alcoholic beverages consumed each day, assessed in varying lengths of time (i.e., 2 weeks, 4 weeks, 6 weeks, etc.). A standard alcoholic beverage is equivalent to: 1, 12 oz. regular beer; 1, 5 oz. glass of wine; 1, mixed drink with one1.5 oz shot; or 1, 1.5 oz shot. A drinking day is measured as any day of the week in which an alcoholic beverage is consumed. Data for drinks per drinking day is gathered using the "Time Line Follow Back" method in which participants are asked to recall their alcohol consumption day by day for a pre-defined set of time.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21-55 years of age with
  • Alcohol Dependence

Exclusion Criteria:

  • Medical Contraindications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746785

United States, New Mexico
The Mind Research Network
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
The Mind Research Network
Principal Investigator: Kent E Hutchison, Ph.D. The Mind Research Network

Responsible Party: Kent Hutchison, Ph.D., Chief Science Officer, The Mind Research Network Identifier: NCT00746785     History of Changes
Other Study ID Numbers: 5R01AA014886 ( U.S. NIH Grant/Contract )
First Posted: September 4, 2008    Key Record Dates
Results First Posted: March 20, 2014
Last Update Posted: March 20, 2014
Last Verified: January 2014

Keywords provided by Kent Hutchison, Ph.D., The Mind Research Network:

Additional relevant MeSH terms:
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents